Research Analysts Issue Forecasts for Alkermes Q1 Earnings

Key Points

• HC Wainwright has raised its Q1 2026 earnings per share estimate for Alkermes from $0.18 to $0.25, while maintaining a "Neutral" rating and a price target of $46.00 on the stock.
• Alkermes reported $0.52 earnings per share for the last quarter, surpassing the consensus estimate of $0.42 by $0.10, despite revenue declining 2.1% year-over-year.
• Several analysts, including UBS and Cantor Fitzgerald, have recently upgraded their ratings on Alkermes, with a consensus rating of "Moderate Buy" and a target price averaging $41.08.

Alkermes plc (NASDAQ:ALKS - Free Report) - Stock analysts at HC Wainwright boosted their Q1 2026 earnings per share estimates for shares of Alkermes in a research note issued to investors on Wednesday, July 30th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of $0.25 for the quarter, up from their prior forecast of $0.18. HC Wainwright has a "Neutral" rating and a $46.00 price objective on the stock. The consensus estimate for Alkermes' current full-year earnings is $1.31 per share. HC Wainwright also issued estimates for Alkermes' Q3 2026 earnings at $0.30 EPS.

Alkermes (NASDAQ:ALKS - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.42 by $0.10. The business had revenue of $390.66 million during the quarter, compared to the consensus estimate of $343.20 million. Alkermes had a return on equity of 24.86% and a net margin of 23.15%. Alkermes's revenue for the quarter was down 2.1% on a year-over-year basis. During the same period in the prior year, the company earned $1.16 EPS.

Several other analysts have also weighed in on ALKS. Wall Street Zen lowered Alkermes from a "strong-buy" rating to a "buy" rating in a research note on Monday, May 5th. Cantor Fitzgerald raised Alkermes to a "strong-buy" rating in a research note on Tuesday, May 13th. Needham & Company LLC reissued a "buy" rating and set a $45.00 price objective on shares of Alkermes in a report on Tuesday, July 29th. UBS Group raised Alkermes from a "neutral" rating to a "buy" rating and raised their price objective for the company from $33.00 to $42.00 in a report on Tuesday, June 17th. Finally, The Goldman Sachs Group started coverage on Alkermes in a report on Tuesday, July 15th. They set a "buy" rating and a $43.00 price objective on the stock. Three analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $41.08.

Alkermes Price Performance

NASDAQ:ALKS traded up $0.06 during trading hours on Friday, hitting $26.55. The company's stock had a trading volume of 1,587,001 shares, compared to its average volume of 2,172,861. The stock has a fifty day simple moving average of $29.21 and a 200-day simple moving average of $30.78. The company has a market capitalization of $4.38 billion, a P/E ratio of 12.76, a PEG ratio of 1.63 and a beta of 0.47. Alkermes has a twelve month low of $25.56 and a twelve month high of $36.45.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Twin Tree Management LP acquired a new position in shares of Alkermes in the 1st quarter valued at about $29,000. Armstrong Advisory Group Inc. acquired a new position in shares of Alkermes in the 2nd quarter valued at about $29,000. Brooklyn Investment Group lifted its stake in shares of Alkermes by 1,071.1% in the 1st quarter. Brooklyn Investment Group now owns 1,054 shares of the company's stock valued at $35,000 after purchasing an additional 964 shares during the period. Quantbot Technologies LP lifted its stake in shares of Alkermes by 54.5% in the 1st quarter. Quantbot Technologies LP now owns 1,091 shares of the company's stock valued at $36,000 after purchasing an additional 385 shares during the period. Finally, USA Financial Formulas acquired a new position in shares of Alkermes in the 1st quarter valued at about $49,000. 95.21% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Alkermes news, SVP Christian Todd Nichols sold 3,334 shares of Alkermes stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $31.09, for a total transaction of $103,654.06. Following the transaction, the senior vice president directly owned 86,208 shares of the company's stock, valued at approximately $2,680,206.72. The trade was a 3.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 4.40% of the company's stock.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.